1. Durable response in the markers of cholestasis through 18 months of open-label extension with obeticholic acid in primary biliary cholangitis. (8th October 2016) Authors: Trauner, M.; Nevens, F.; Andreone, P.; Mazzella, G.; Strasser, S.; Bowlus, C.; Invernizzi, P.; Drenth, J.; Pockros, P.; Regula, J.; Floreani, A.; Hohenester, S.; Luketic, V.; Shiffman, M.; van Erpecum, K.; Vargas, V.; Vincent, C.; Hansen, B.; MacConell, L.; Marmon, T. Journal: Digestive and liver disease Issue: Volume 48(2016)Supplement 3 Page Start: e236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Durable response in the markers of cholestasis through 24 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Issue 1 (16th February 2017) Authors: Andreone, P.; Floreani, A.; Invernizzi, P.; Mazzella, G.; Owens-Grillo, J.; Smoot Malecha, E.; MacConell, L. Journal: Digestive and liver disease Issue: Volume 49:Issue 1(2017)Supplement Page Start: e21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Obeticholic acid (OCA) improves non-invasive markers of fibrosis in patients with non-alcoholic steatohepatitis (NASH): a secondary analysis of the phase 3 Regenerate study. (February 2020) Authors: Anstee, Q.M.; Harrison, S.; Sanyal, Arun J.; Ratziu, V.; Rinella, M.; Younossi, Z.Y.; Boursier, J.; Francque, S.; Geerts, A.; Petta, S.; Bugianesi, E-; Romero-Gomez, M.; Schattenberg, J.M.; Sarkar, S.; Bonacini, M.; Yataco, M.; Porayko, M.; Siddique, A.; Dufour, J.; Ferro, T. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e41 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Obeticholic Acid Treatment in Patients with Non-Alcoholic Steatohepatitis: A Secondary Analysis of the Regenerate Study Across Fibrosis Stages. (February 2020) Authors: Sanyal, A.J.; Ratziu, V.; Loomba, R.; Rinella, M.; Anstee, Q.M.; Goodman, Z.; Bedossa, P.; Khalili, M.; Boursier, J.; Stinton, L.; Marchesini, G.; Allison, M.; George, J.; Arkkila, P.; Bugianesi, E.; Zaru, L.; MacConell, L.; Shringarpure, R. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Durable response in the markers of cholestasis through 5 years of open-label extension study of obeticholic acid in primary biliary cholangitis. (February 2020) Authors: Nevens, F.; Shiffman, M.L.; Drenth, J.P.H.; Bowlus, C.L.; Vargas, V.; Andreone, P.; van Erpecum, K.; Floreani, A.; Liberman, A.; Pencek, R.; Malecha, E. Smoot; MacConell, L.; Trauner, M. Journal: Digestive and liver disease Issue: Volume 52(2020)Supplement 1 Page Start: e30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Long-term efficacy and safety of obeticholic acid in patients with PBC from the POISE trial grouped biochemically by risk of disease progression. (March 2021) Authors: Bowlus, C.L.; Trauner, M.; Liberman, A.; Malecha, E.; MacConell, L.; Kremer, A.E.; Nevens, F.; Floreani, A. Journal: Digestive and liver disease Issue: Volume 53:(2021)Supplement 1 Page Start: S18 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. (February 2019) Authors: Bowlus, C.L.; Pockros, P.J.; Kremer, A.E.; Parés, A.; Forman, L.M.; Drenth, J.P.H.; Ryder, S.; Terracciano, L.; Floreani, A.; Jin, Y.; Lieberman, A.; Pencek, R.; Iloeje, U.; MacConell, L.; Bedossa, P. Journal: Digestive and liver disease Issue: Volume 51(2019)Supplement 1 Page Start: e19 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Is insulin the most effective injectable antihyperglycaemic therapy?. Issue 2 (9th November 2014) Authors: Buse, J. B.; Peters, A.; Russell‐Jones, D.; Furber, S.; Donsmark, M.; Han, J.; MacConell, L.; Maggs, D.; Diamant, M. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 2(2015:Feb.) Page Start: 145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Durable response in the markers of cholestasis through 36 months of open-label extension with obeticholic acid in Italian patients with primary biliary cholangitis. Issue 1 (February 2018) Authors: Andreone, P.; Floreani, A.; Invernizzi, P.; Mazzella, G.; Owens-Grillo, J.; Malecha, E. Smoot; MacConell, L. Journal: Digestive and liver disease Issue: Volume 50:Issue 1(2018)Supplement Page Start: 26 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗